Advanced Image Analysis for Personalized Cancer Care

Nucs AI provides advanced AI-driven solutions that deliver precise, actionable insights for the clinical management of prostate cancer, empowering healthcare professionals.

Contact Us

Nucs AI empowers physicians
with cutting-edge AI to make faster, personalized decisions for better cancer care.

Step 1
Select Scan

Upload imaging studies individually, in bulk, or through PACS integration.

Step 2
AI Analysis

Our end-to-end deep learning model processes each scan in 7-10 minutes.

Step 3
Physician Review

Users review AI outputs. In over 50% of cases no manual adjustments are needed.

Step 4
Report Generation

Receive evidence-based reports that translate complex data into meaningful, actionable insights for patient care.

Problem & Solutions

How Nucs AI is Addressing Critical Challenges in Prostate Cancer Care

The need for personalized cancer care is more critical than ever. Nucs AI delivers advanced solutions to meet rising demands.

92%

AI accuracy in identifying PSMA-positive lesions improves efficiency and reader confidence

<1 Min

Under a minute analysis — with over 50% requiring no manual edits, and the rest needing minimal adjustment

Tumor Burden and Progression Assessment

Whole-body tumor analysis and predictive modeling, enables personalized therapy, assesses disease progression, as well as timely monitoring and clinical intervention.

AI-Driven Workflow Efficiency

Cloud-based access to automated lesion detection and staging reduces clinician workload, streamlines reporting, and helps meet growing diagnostic demand—without adding to specialist staffing needs.

Predictive & Standardized Reporting

Imaging biomarkers stratify patients before therapy, while AI-driven quantification ensures reproducible, consistent reporting across institutions, avoiding unnecessary treatments.

Nucs AI Products

Explore the future of prostate cancer care with Nucs AI

Comprehensive Tumor Analysis

DeepPSMAᵀᴹ

Fast and reproducible whole-body tumor burden quantification in PSMA-PET/CT imaging, delivering critical insights on tumor characteristics.
Request demo
Learn More
Personalized Treatment Predictions

SelectPSMAᵀᴹ

AI-powered predictions of patient outcomes following treatment with PSMA-targeted radiopharmaceuticals, helping to avoid ineffective treatments and side effects.
Request demo
Learn More
AI-Image Comparison

TrackPSMA

AI technology for fully automated treatment response evaluation in prostate cancer using PSMA-PET/CT, aiming to identify early treatment progression in patients with no clinical benefit.
Request demo
Learn More

Expanding

Nucs AI is expanding beyond prostate cancer toward a broader AI ecosystem in healthcare. We are building an all-in-one platform that unifies imaging, decision support, and clinical workflows. Our vision is to scale seamlessly across care settings, enabling a more connected and evidence-driven future.
Coming Soon

1.Gafita A, Voter A, Shesadri S, et al. Initial experience with [177Lu]Lu-PSMA-617 after regulatory approval for metastatic castration-resistant prostate cancer: efficacy, safety, and outcome prediction. J Nucl Med. 2024;65(11):1724–1730. doi:10.2967/jnumed.124.267723
2. Mahal BA, Butler S, Franco I, et al. Progression to metastatic prostate cancer in the United States. J Natl Cancer Inst. 2020;112(10):1022-1029. doi:10.1093/jnci/djaa015
3. Harolds JA, Parikh JR, Bluth EI, Dutton SC, Recht MP. Burnout of radiologists: frequency, risk factors, and remedies: a report of the ACR Commission on Human Resources. J Am Coll Radiol. 2016;13(4):411-416. doi:10.1016/j.jacr.2015.11.003
4. Medscape. 2023 Radiologist Burnout & Depression Report. Medscape. Published January 20, 2023. Accessed June 12, 2025. https://www.medscape.com/slideshow/2023-lifestyle-radiologist-6015865
5. Khurana A, Parikh JR. The growing demand for imaging and the shortage of radiologists: a looming crisis. Radiol Clin North Am. 2021;59(1):1-7. doi:10.1016/j.rcl.2020.08.002